What happened
Pakistan's Drug Regulatory Authority of Pakistan (DRAP) made 2D barcoding and serialisation mandatory for every registered pharmaceutical product made locally or imported on or after 9 October 2026. The requirement carries a unique serial number on each saleable pack, not just a product or batch identifier.
On 4 November, Federal Health Minister Syed Mustafa Kamal went further. At a review meeting in Islamabad he warned that companies failing to submit the required product data face legal action and that their production facilities could be sealed. Officials said around 80% of companies had started implementation.
This is the mandate the 3 November post pointed at: a government doing this instead of a brand.
What the codes actually have to carry
The specificity is the interesting part:
- A GS1 DataMatrix 2D barcode with product identification and batch-level information
- A unique serial number on each saleable pack
- Consumer verification by mobile app: authenticity, manufacturer, batch, expiry date and official price
The second bullet is the one that matters. A GS1 DataMatrix on its own identifies a product and a batch, which is what a barcode on a cereal box does. A unique serial per saleable pack is what makes the pack individually traceable.
DRAP's circular of 8 October confirms Phase I covers all locally manufactured and imported products, effective from 9 October 2026, to curb counterfeit medicines and support product recalls.
A barcode that identifies a batch tells a regulator a problem is somewhere in that batch. A serial that identifies one pack tells them exactly which packs to pull.
The enforcement design is the story
Regulators have required codes before. What differs here is what happens when a company does not comply.
The threat is sealing the manufacturing facility. That stops a CFO, not a marketing department, and it is why 80% of the industry moved in under two months.
Three things make DRAP's approach specific:
- The deadline is on the product, not the company. Batches made before 9 October 2026 are exempt and may continue to be imported, distributed and sold. The incentive is to convert the line, not argue with the system.
- Imported product is covered too. Office memoranda directed importers to coordinate with foreign suppliers so the codes are on the packaging before dispatch. A market that imports most of what it sells cannot leave the serial out.
- The data submission is the obligation, not the printing. A code on the pack is worthless without a matching record in the national system.
Where the industry is pushing back
The Pakistan Pharmaceutical Manufacturers Association supports the system in principle but wants a realistic timeline. Chairman Usman Shaukat said the industry was not equipped with the printing technology required, and warned genuine medicines could disappear from the market if companies cannot equip in time.
A recall system that only works when the code is on the pack has a blind spot, and the packs without codes are the older stock, exactly the stock most likely to be diverted.
Source and caveats
Medical News Pakistan, 4 November 2026, reporting a review meeting in Islamabad and a statement by the federal health minister. The compliance date and GS1 specification are from DRAP's circular of 8 October 2026. The 80% figure is a government statement, not an audited one.
Key takeaways
- DRAP made 2D barcoding and serialisation mandatory for all medicines manufactured or imported on or after 9 October 2026.
- On 4 November the health minister warned non-compliant firms face legal action and possible plant sealing.
- Around 80% of companies had begun implementation; formal notices were going to the rest.
- The requirement is a GS1 DataMatrix plus a unique serial per saleable pack, with consumer verification by mobile app.
- Pre-deadline batches are exempt, and the industry has warned genuine product could leave the market.
What this means for a brand owner
The lesson is about where the enforcement bite goes, not always where you would design it.
- Codes with no penalty behind them are decoration. DRAP led with a rule, attached a consequence, then said the consequence would be applied.
- A serial per pack is the unit that makes a recall possible. If your authentication identifies a batch, you can only act on a batch, which means destroying good product.
- The record is the asset, not the mark. A printed code is a copyable string. A code bound to a record the brand controls, resolving to one unit, is not.
- Plan for the transition window. A regime that exempts pre-deadline stock creates a period where some packs are verifiable and some are not. If your design assumes every pack can be verified, you will be wrong for a quarter after any comparable rule lands.